tetano
Editor, Senior Moderator
Kidney360
. 2024 Jul 8.
doi: 10.34067/KID.0000000000000498. Online ahead of print. Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan
Ryousuke Aoki[SUP] 1 2 [/SUP], Yoshihito Nihei[SUP] 1 3 [/SUP], Keiichi Matsuzaki[SUP] 4 2 [/SUP], Hitoshi Suzuki[SUP] 5 2 [/SUP], Masao Kihara[SUP] 1 2 [/SUP], Asa Ogawa[SUP] 6 [/SUP], Tomoya Nishino[SUP] 7 2 [/SUP], Satoru Sanada[SUP] 3 [/SUP], Shinya Yokote[SUP] 8 [/SUP], Masahiro Okabe[SUP] 9 [/SUP], Sayuri Shirai[SUP] 10 2 [/SUP], Akihiro Fukuda[SUP] 11 2 [/SUP], Junichi Hoshino[SUP] 12 [/SUP], Daisuke Kondo[SUP] 13 [/SUP], Takashi Yokoo[SUP] 14 2 [/SUP], Naoki Kashihara[SUP] 15 2 [/SUP], Ichiei Narita[SUP] 16 2 [/SUP], Yusuke Suzuki[SUP] 1 2 [/SUP]
Affiliations
Background: In the past three years, cases of gross hematuria (GH) after the vaccination for coronavirus disease 2019 (COVID-19) in IgA nephropathy (IgAN) patients have been frequently reported worldwide. However, the post-event renal prognosis of these patients, their clinical backgrounds, and underlying mechanisms remain unknown. Therefore, we conducted a nationwide multicenter prospective cohort study in Japan.
Methods: We analyzed laboratory findings at the time of the first presentation to the hospital, and 3 and 6 months after in patients with GH after the vaccination, and histopathological findings in their kidney biopsy specimens. Moreover, changes in pathological biomarkers of IgAN such as galactose-deficient IgA1 (Gd-IgA1) and its immune complexes (ICs) were also evaluated.
Results: During the study period, 127 newly presenting with GH after the vaccination were enrolled, with a clear female bias (73.2%). GH was observed after the second or subsequent vaccinations in most patients (92.9%). Of the 37 patients undergoing kidney biopsy prior to the vaccination, 36 patients had been diagnosed with IgAN/IgA vasculitis (IgAV). In remaining 90 patients, 69 of the 70 who newly underwent kidney biopsy were diagnosed with IgAN (N=67)/IgAV (N=2). Their histopathology did not show a high incidence of acute lesions such as endocapillary hypercellularity and crescentic lesions. Most cases showed a temporary increase in proteinuria, but no sustained worsening in renal function. Among the biomarkers measured, serum Gd-IgA1 and ICs were comparable throughout the observation period, however, only urinary Gd-IgA1 was increased at the time of GH.
Conclusions: We found that GH after the vaccination is more likely to occur in IgAN/IgAV patients, with a female bias, but without progressive exacerbation of renal function. Although further investigation is needed regarding causal relationship between vaccination and GH, this study provides many insights into the molecular mechanisms of GH.
. 2024 Jul 8.
doi: 10.34067/KID.0000000000000498. Online ahead of print. Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan
Ryousuke Aoki[SUP] 1 2 [/SUP], Yoshihito Nihei[SUP] 1 3 [/SUP], Keiichi Matsuzaki[SUP] 4 2 [/SUP], Hitoshi Suzuki[SUP] 5 2 [/SUP], Masao Kihara[SUP] 1 2 [/SUP], Asa Ogawa[SUP] 6 [/SUP], Tomoya Nishino[SUP] 7 2 [/SUP], Satoru Sanada[SUP] 3 [/SUP], Shinya Yokote[SUP] 8 [/SUP], Masahiro Okabe[SUP] 9 [/SUP], Sayuri Shirai[SUP] 10 2 [/SUP], Akihiro Fukuda[SUP] 11 2 [/SUP], Junichi Hoshino[SUP] 12 [/SUP], Daisuke Kondo[SUP] 13 [/SUP], Takashi Yokoo[SUP] 14 2 [/SUP], Naoki Kashihara[SUP] 15 2 [/SUP], Ichiei Narita[SUP] 16 2 [/SUP], Yusuke Suzuki[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38976886
- DOI: 10.34067/KID.0000000000000498
Background: In the past three years, cases of gross hematuria (GH) after the vaccination for coronavirus disease 2019 (COVID-19) in IgA nephropathy (IgAN) patients have been frequently reported worldwide. However, the post-event renal prognosis of these patients, their clinical backgrounds, and underlying mechanisms remain unknown. Therefore, we conducted a nationwide multicenter prospective cohort study in Japan.
Methods: We analyzed laboratory findings at the time of the first presentation to the hospital, and 3 and 6 months after in patients with GH after the vaccination, and histopathological findings in their kidney biopsy specimens. Moreover, changes in pathological biomarkers of IgAN such as galactose-deficient IgA1 (Gd-IgA1) and its immune complexes (ICs) were also evaluated.
Results: During the study period, 127 newly presenting with GH after the vaccination were enrolled, with a clear female bias (73.2%). GH was observed after the second or subsequent vaccinations in most patients (92.9%). Of the 37 patients undergoing kidney biopsy prior to the vaccination, 36 patients had been diagnosed with IgAN/IgA vasculitis (IgAV). In remaining 90 patients, 69 of the 70 who newly underwent kidney biopsy were diagnosed with IgAN (N=67)/IgAV (N=2). Their histopathology did not show a high incidence of acute lesions such as endocapillary hypercellularity and crescentic lesions. Most cases showed a temporary increase in proteinuria, but no sustained worsening in renal function. Among the biomarkers measured, serum Gd-IgA1 and ICs were comparable throughout the observation period, however, only urinary Gd-IgA1 was increased at the time of GH.
Conclusions: We found that GH after the vaccination is more likely to occur in IgAN/IgAV patients, with a female bias, but without progressive exacerbation of renal function. Although further investigation is needed regarding causal relationship between vaccination and GH, this study provides many insights into the molecular mechanisms of GH.